Why Argen X SE ADR (ARGX) Stock Is Rising
As of 2026-08-25, Argen X SE ADR (ARGX) has a next-year EPS growth estimate of 32.73%. Featured in 3 EPS revision reports, most recently on 2026-08-20.
Why ARGX Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Argen X SE ADR's next-year EPS growth estimate from 31.95% to 32.90% on 2026-08-17.
- ·Current-Year Growth: Projected at 48.06%, supporting the forward estimate revision.
News Context
The stock’s rise is primarily tied to an EPS estimate upgrade, with next-year growth estimates raised from 31.95% to 32.90% on August 17 and now at 32.73%. The upgrade plausibly reflects positive Phase 3 ALKIVIA trial results for Vyvgart in autoimmune myositis, a likely product expansion catalyst. Momentum has continued, with additional headlines covering the drug’s success and argenx’s planned $2.2B acquisition of Forte Biosciences.
Generated 2026-08-25 · news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 32.73%
- EPS growth this year
- 48.06%
- EPS next quarter (est)
- $7.65
- Last price
- $1019.49
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 32.73% | 48.06% | $7.65 | $1019.49 |
| 2026-08-24 | 32.73% | 48.06% | $7.65 | $1011.11 |
| 2026-08-23 | 32.63% | 48.11% | $7.65 | $1039.78 |
| 2026-08-21 | 32.63% | 48.11% | $7.65 | $1039.78 |
| 2026-08-20 | 32.63% | 48.11% | $7.65 | $1038.12 |
| 2026-08-19 | 32.63% | 48.11% | $7.65 | $1032.86 |
| 2026-08-18 | 32.63% | 48.11% | $7.65 | $992.99 |
| 2026-08-17 | 32.90% | 47.55% | $7.64 | $987.84 |
| 2026-08-16 | 31.95% | 47.12% | $7.60 | $851.29 |
| 2026-08-14 | 31.62% | 46.68% | $7.56 | $851.29 |
| 2026-08-13 | 31.59% | 46.59% | $7.56 | $856.94 |
| 2026-08-12 | 32.03% | 46.28% | $7.62 | $876.00 |
| 2026-08-11 | 32.33% | 45.68% | $7.56 | $864.74 |
| 2026-08-10 | 32.33% | 45.68% | $7.56 | $866.11 |
| 2026-08-09 | 32.33% | 45.68% | $7.56 | $865.04 |
| 2026-08-07 | 32.33% | 45.68% | $7.56 | $865.04 |
| 2026-08-06 | 32.33% | 45.68% | $7.56 | $875.30 |
| 2026-08-05 | 32.51% | 44.67% | $7.58 | $867.94 |
| 2026-08-04 | 32.61% | 44.39% | $7.58 | $844.50 |
| 2026-08-03 | 32.89% | 44.39% | $7.58 | $830.79 |
| 2026-08-02 | 32.89% | 44.39% | $7.58 | $853.82 |
| 2026-07-31 | 32.89% | 44.39% | $7.58 | $853.82 |
| 2026-07-30 | 32.89% | 44.39% | $7.58 | $872.58 |
| 2026-07-29 | 33.01% | 44.51% | $7.57 | $882.56 |
| 2026-07-28 | 33.25% | 44.53% | $7.58 | $872.23 |
| 2026-07-27 | 33.50% | 44.62% | $7.60 | $888.82 |
| 2026-07-26 | 33.17% | 44.53% | $7.62 | $918.22 |
| 2026-07-24 | 33.17% | 44.53% | $7.58 | $918.22 |
| 2026-07-23 | 34.87% | 37.64% | $6.54 | $924.60 |
| 2026-07-22 | 35.68% | 35.38% | $6.36 | $851.72 |
Reports Featuring ARGX
Recent News
- Argenx Stock Heads for Record After Blockbuster Drug Delivers Another WinBarrons.com
- Argenxs stock rises on Phase III autoimmune myositis victoryClinical Trials Arena
- argenx Phase 3 ALKIVIA Trial Meets Primary Endpoint in Autoimmune MyositisInvestorsHub
- Argenx's Vyvgart Scored Another Win - Why Shares Bolted HigherInvestor's Business Daily
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisBusiness Wire
- European Indexes Start Week Mostly Higher, Boosted by Tech, Pharma StocksThe Wall Street Journal
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisGlobeNewswire
- Forte Biosciences shares surge after argenx agrees to acquire company for $2.2BProactive
- Argenx to acquire Forte in $2.2B deal for differentiated immune drugBioPharma Dive
- FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug MakerStocktwits
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Argen X SE ADR (ARGX) stock go up recently?▾
Argen X SE ADR (ARGX) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 31.95% to 32.90% on 2026-08-17. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Argen X SE ADR's next-year EPS growth estimate?▾
As of 2026-08-25, Argen X SE ADR (ARGX) has a next-year EPS growth estimate of 32.73%, based on analyst consensus.
When was the latest EPS estimate revision for ARGX?▾
The most recent revision occurred on 2026-08-24, when analysts adjusted the next-year EPS growth estimate from 32.63% to 32.73%.
What sector and industry does Argen X SE ADR belong to?▾
Argen X SE ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ARGX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Argen X SE ADR (ARGX) appears here because it was detected by our daily top-EPS-revision-performer screen.